EVMN
INSIDER BUYEvommune, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeEvommune's lead candidate EVO756 failed its Phase 2b primary endpoint in chronic spontaneous urticaria (CSU) in late June 2026, prompting a strategic pivot to atopic dermatitis and migraine indications. The company reported a significant earnings miss in Q2 (net loss of $32.2M vs. expectations, EPS of -$0.89 vs. consensus -$0.67), driving a 40%+ stock decline to ~$14 by early August despite maintaining $288M in cash and initiating a migraine Phase 2b trial.
Red flags
- •Phase 2b CSU trial failed primary endpoint (UAS7), eliminating lead indication
- •EPS miss of 33% vs. consensus (-$0.89 vs. -$0.67)
- •Net loss more than doubled year-over-year ($32.2M in Q2 2026 vs. $13.6M in Q2 2025)
- •Stock declined ~40% from ~$23-24 to $14 following CSU failure
- •Two major analyst initiations (RBC, Oppenheimer) with bullish ratings were explicitly predicated on CSU success; credibility of coverage now questioned
- •Migraine Phase 2b data not expected until 2027, creating extended period of binary execution risk with no near-term catalysts
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).